ORIC PHARMACEUTICALS, INC. Research and Development Expense
ORIC PHARMACEUTICALS, INC. (ORIC) reported Research and Development Expense of $7.72 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-08-05
- ORIC PHARMACEUTICALS, INC. research and development expense for the quarter ending 2020-06-30 was $7.72M, a 53.23% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. research and development expense for the quarter ending 2020-03-31 was $7.25M, a 39.18% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-06-30 was $5.04M.
- ORIC PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-03-31 was $5.21M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2020-06-30 | $7.72M 10-Q · filed 2020-08-05 | $14.98M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $7.25M 10-Q · filed 2020-05-20 | |
| 2019-06-30 | $5.04M 10-Q · filed 2020-08-05 | $10.25M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $5.21M 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |